Prescription Opioid Misuse Assessment (POMA 4)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03195374|
Recruitment Status : Unknown
Verified June 2017 by University Hospital, Clermont-Ferrand.
Recruitment status was: Not yet recruiting
First Posted : June 22, 2017
Last Update Posted : June 22, 2017
|Condition or disease||Intervention/treatment|
|Chronic Pain||Other: Prescription Opioid Misus Index|
This is an observational study . Each addictovigilance centre will contact Pain Clinics in order to enroll patients meeting the inclusion criteria. The questionnaires will be prepared and sent to the participating centres by the coordinating centre (Clermont-Ferrand). Participation in the study will be systematically proposed by the physician during the study inclusion period (3 months). Patients meeting all inclusion criteria will be enrolled after receiving oral information about the study.
This questionnaire can be semi-directed (doctor / nurse / CRA) and will be carried out during a consultation as part of their usual care. Answering the questionnaire should take no more than 10 minutes. No additional diagnostic or monitoring procedures will be applied to patients.
|Study Type :||Observational|
|Estimated Enrollment :||1068 participants|
|Official Title:||Assessment of the Prevalence of Analgesics Opioid Misuse in Chronic Non-cancer Pain Patients|
|Estimated Study Start Date :||February 2018|
|Estimated Primary Completion Date :||May 2018|
|Estimated Study Completion Date :||November 2018|
Patients with chronic non-cancer pain
Each addictovigilance centre will contact Pain Clinics in order to enroll patients meeting the inclusion criteria.
Other: Prescription Opioid Misus Index
Opioid misuse will be assessed by the Prescription Opioid Misuse Index (POMI) scale. A score ≥ 2 is considered positive and will define a misuse behavior.
- Opioid misuse will be assessed by the Prescription Opioid Misuse Index (POMI) scale [ Time Frame: at day 1 ]A score ≥ 2 is considered positive and will define a misuse behavior
- Analgesic opioids used by the patient will be collected in the questionnaire [ Time Frame: at day 1 ]
- Patients' profiles and associated risk factors of opioid misuse will be described through socio-demographic contained in the questionnaire [ Time Frame: at day 1 ]age, gender, family situation, employment status) and clinical data (type of pain, age of painful pathology, psychiatric comorbidities, abuse of other substances, etc
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03195374
|Contact: Patrick LACARIN||04 73 75 11 firstname.lastname@example.org|
|CHU de Clermont-Ferrand|
|Clermont-Ferrand, Auvergne, France, 63003|
|Contact: Patrick LACARIN 04 73 75 11 95 email@example.com|
|Principal Investigator: Nicolas AUTHIER|
|Principal Investigator:||Nicolas AUTHIER||CHU de Clermont-Ferrand|